SolventumFRA:KB7 -0.30%26 3-Year ROIIC % is 76.43 as of Dec. 2025, which is 0% below its 10-year median of 76.45. GuruFocus rates FRA:KB7 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 798 Medical Devices & Instruments companies, Solventum ranks better than 86.72% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Solventum's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 76.43%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Solventum's 3-Year ROIIC % or its related term are showing as below:
FRA:KB7's 3-Year ROIIC % is ranked better than 86.72% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs FRA:KB7: 76.43
Solventum (FRA:KB7) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Solventum 3-Year ROIIC % Related Terms
Solventum 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Solventum's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:KB7 vs COO, ALGN, BAX: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Solventum's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solventum 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Solventum's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Solventum's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Solventum (FRA:KB7) has a 3-Year ROIIC % of 76.43 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Solventum and its competitors. This is near median its historical median of 76.45. Over the past decade, Solventum's 3-Year ROIIC % has ranged from 76.43 to 76.46. According to the industry distribution chart, Solventum ranks #106 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 13.3%.
Is Solventum's 3-Year ROIIC % too high?
Solventum's current 3-Year ROIIC % of 76.43 is near median its 10-year median of 76.45. Over the past 10 years, this metric has ranged from a low of 76.43 to a high of 76.46. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.57. Solventum's value of 76.43 is 4768.2% above this industry median. Based on the distribution chart, Solventum ranks #106 out of 798 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Solventum has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's 3-Year ROIIC % compare to COO and ALGN?
According to the Medical Devices & Instruments industry distribution chart, Solventum ranks #106 out of 798 companies for 3-Year ROIIC %. This places Solventum in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.57. Solventum's value of 76.43 is 4768.2% above this benchmark. Historically, Solventum's own 3-Year ROIIC % has ranged from 76.43 to 76.46 over the past decade. While the company's 10-year median is 76.45 vs. the industry median of 1.57, Solventum has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.57, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solventum's current 3-Year ROIIC % of 76.43 is 4768.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Solventum and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solventum's current 3-Year ROIIC % is 76.43, which is near median its own 10-year median of 76.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (FRA:KB7) has a current 3-Year ROIIC % of 76.43. The current 3-Year ROIIC % is 76.43, which is near median its 10-year median of 76.45 and 4768.2% above the Medical Devices & Instruments industry median of 1.57. Solventum's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Solventum (FRA:KB7), the current 3-Year ROIIC % is 76.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
26GF Score
Get the complete analysis for FRA:KB7
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KB7 has been successfully added to your 
